Form 8-K - Current report:
SEC Accession No. 0001829126-25-001180
Filing Date
2025-02-24
Accepted
2025-02-24 08:31:01
Documents
17
Period of Report
2025-02-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cyclacel_8k.htm   iXBRL 8-K 30695
2 EXHIBIT 10.1 cyclacel_10-1.htm EX-10.1 6259
3 GRAPHIC ex10-1_001.jpg GRAPHIC 779399
4 GRAPHIC ex10-1_002.jpg GRAPHIC 427268
  Complete submission text file 0001829126-25-001180.txt   1838957

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE cycc-20250220.xsd EX-101.SCH 3744
6 XBRL DEFINITION FILE cycc-20250220_def.xml EX-101.DEF 26582
7 XBRL LABEL FILE cycc-20250220_lab.xml EX-101.LAB 36614
8 XBRL PRESENTATION FILE cycc-20250220_pre.xml EX-101.PRE 25206
19 EXTRACTED XBRL INSTANCE DOCUMENT cyclacel_8k_htm.xml XML 5625
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 25654337
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)